The clinical impact of recent advances in LC-MS for cancer biomarker discovery and verification
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Mass spectrometry (MS) -based proteomics has become an indispensable tool with broad applications in systems biology and biomedical research. With recent advances in liquid chromatography (LC) and MS instrumentation, LC-MS is making increasingly significant contributions to clinical applications, especially in the area of cancer biomarker discovery and verification. To overcome challenges associated with analyses of clinical samples (for example, a wide dynamic range of protein concentrations in bodily fluids and the need to perform high throughput and accurate quantification of candidate biomarker proteins), significant efforts have been devoted to improve the overall performance of LC-MS-based clinical proteomics platforms. Reviewed here are the recent advances in LC-MS and its applications in cancer biomarker discovery and quantification, along with the potentials, limitations and future perspectives.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ross, P. L., Huang, Y. N., Marchese, J. N., Williamson, B., Parker, K., Hattan, S., Khainovski, N., Pillai, S., Dey, S., Daniels, S., et al. (2004) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m400129-mcp200 · Cited by 4,401
Blume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738 · cited 1×
“Alterations in phosphorylation are highly correlated to pathway activities, which lead to oncogenesis.[132] However, due to low abundance and stoichiometry, accurate quantification of phosphosites remains a challenge.”
Gillet, L. C., Navarro, P., Tate, S., Röst, H., Selevsek, N., Reiter, L., Bonner, R., & Aebersold, R. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.o111.016717 · Cited by 2,877
Protein biomarker discovery and validation: the long and uncertain path to clinical utility
Rifai, N., Gillette, M. A., & Carr, S. A. (2006) · Nature Biotechnology · doi:10.1038/nbt1235 · Cited by 1,867 · cited 1×
“[5– 8] However, due to the wide dynamic range of protein abundances, the potential presence of an array of post-translational modifications (PTMs) and the absence of protein amplification methods, candidate protein biomarkers pose tremendous challenges for the reliable and robust measurement of low-abundance protein b…”
Phases of Biomarker Development for Early Detection of Cancer
Pepe, M. S., Etzioni, R., Feng, Z., Potter, J. D., Thompson, M. L., Thornquist, M., Winget, M., & Yasui, Y. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.14.1054 · Cited by 1,686
Mass spectrometry–based proteomics turns quantitative
Ong, S.-E., & Mann, M. (2005) · Nature Chemical Biology · doi:10.1038/nchembio736 · Cited by 1,572
Selected reaction monitoring–based proteomics: workflows, potential, pitfalls and future directions
Picotti, P., & Aebersold, R. (2012) · Nature Methods · doi:10.1038/nmeth.2015 · Cited by 1,302 · cited 1×
“Challenges in targeted proteomics quantification One of the biggest challenges in biomarker verification, with targeted proteomics quantification, is the lack of sufficient sensitivity for detecting extremely low-abundance proteins,[27] especially in bodily fluids.”
Peterson, A. C., Russell, J. D., Bailey, D. J., Westphall, M. S., & Coon, J. J. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.o112.020131 · Cited by 1,288 · cited 2×
“PRM also achieves comparable dynamic range and linearity, but with less precision.[24] Other PRM-related studies, such as quality control investigation,[89] high-performance parameter optimization,[25] and precise quantification, and workflow of PRM data acquisition and processing,[90] have been reported recently.”
Functional and quantitative proteomics using SILAC
Mann, M. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2067 · Cited by 931
Quantitative mass spectrometry in proteomics: critical review update from 2007 to the present
Bantscheff, M., Lemeer, S., Savitski, M. M., & Kuster, B. (2012) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-012-6203-4 · Cited by 801
Cited by
Detection and localization of surgically resectable cancers with a multi-analyte blood test
Cohen, J. D., Li, L., Wang, Y., Thoburn, C., Afsari, B., Danilova, L., Douville, C., Javed, A. A., Wong, F., Mattox, A., et al. (2018) · Science · doi:10.1126/science.aar3247 · Cited by 2,783
Alarmins in chronic noncommunicable diseases: Atherosclerosis, diabetes and cancer
Boteanu, R. M., Suica, V. I., Uyy, E., Ivan, L., Dima, S. O., Popescu, I., Simionescu, M., & Antohe, F. (2017) · Journal of Proteomics · doi:10.1016/j.jprot.2016.11.006 · Cited by 38
Abdul-Khalek, N., Picciani, M., Shouman, O., Wimmer, R., Overgaard, M. T., Wilhelm, M., & Gregersen Echers, S. (2025) · Journal of Proteome Research · doi:10.1021/acs.jproteome.4c00973 · Cited by 13
Metadata
- Authors
- Wang, H., Shi, T., Qian, W.-J., Liu, T., Kagan, J., Srivastava, S., Smith, R. D., Rodland, K. D., & Camp, D. G.
- Venue
- Expert Review of Proteomics
- Publisher
- Informa UK Limited
- Published
- 2015-12-19
- Volume
- 13
- Issue
- 1
- Pages
- 99-114
- ISSN
- 1478-9450 (ISSN-L)
- 1744-8387
- OpenAlex
- W2180723850
- Cited by
- 61
- References
- 13
- FWCI
- 1.98
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The clinical impact of recent advances in LC-MS for cancer biomarker discovery and verification. https://app.cochat.ai/papers/10.1586/14789450.2016.1122529
- The paper
- Wang, H., Shi, T., Qian, W.-J., Liu, T., Kagan, J., Srivastava, S., Smith, R. D., Rodland, K. D., & Camp, D. G. (2016). The clinical impact of recent advances in LC-MS for cancer biomarker discovery and verification. Expert Review of Proteomics. https://doi.org/10.1586/14789450.2016.1122529
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.